Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 3Terminated 2

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 3

Sponsor

Conditions

Pain 3Neoplasms 2Cancer Pain 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Tapentadol × Clear all
NCT00472303 2019-11-04

A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine

Grünenthal GmbH

Phase 3 Completed
622 enrolled 31 charts

Cancer Pain, Neoplasms, Pain

NCT01165281 2017-07-21

A Safety and Efficacy Study of JNS024 Extended Release (ER) in Japanese and Korean Patients With Chronic Malignant Tumor-Related Cancer Pain

Janssen Research & Development, LLC

Phase 3 Completed
343 enrolled 15 charts

Pain

NCT00805142 2013-07-29

Phase 2 Study of Tapentadol Prolonged Release in Cancer Pain Participants

Janssen Pharmaceutical K.K.

Phase 2 Completed
78 enrolled 16 charts

Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡